Literature DB >> 1277503

Methotrexate in blood, urine, and cerebrospinal fluid of children receiving high doses by infusion.

Y Wang, E Lantin, W W Sutow.   

Abstract

Methotrexate was determined in plasma (31 patients), urine (eight patients), and cerebrospinal fluid (two patients) after high doses (35 to 150 mg/kg) by infusion, with citrovorum factor rescue. Concentrations in plasma were proportional to dose at 6, 24, 72 h after beginning treatment, but this trend was very minimal for samples obtained at 48 h. Clinical toxicity probably will not be serious if the methotrexate concentration in the serum is less than 4.5 X 10(-6) mol/liter at 48 h after the start of a 6-h infusion. In both of the two patients so examined, therapeutic concentrations appeared in cerebrospinal fluid after intravenous infusion of the drug. A kinetic enzymic method, radioassay, and radioimmunoassay all yielded similar results for drug concentrations.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1277503

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  8 in total

1.  Osmotic blood-brain barrier disruption. Computerized tomographic monitoring of chemotherapeutic agent delivery.

Authors:  E A Neuwelt; K R Maravilla; E P Frenkel; S I Rapaport; S A Hill; P A Barnett
Journal:  J Clin Invest       Date:  1979-08       Impact factor: 14.808

2.  Effective therapy for Burkitt's lymphoma: high-dose cyclophosphamide + high-dose methotrexate with coordinated intrathecal therapy.

Authors:  I Ramirez; M P Sullivan; Y Wang; R G Martin; J J Butler
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 3.  Clinical pharmacokinetics of methotrexate in children.

Authors:  Y M Wang; T Fujimoto
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

Review 4.  The practical benefits of pharmacokinetics in the use of antineoplastic agents.

Authors:  C Erlichman; R C Donehower; B A Chabner
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

5.  Central nervous system pharmacology of Baker's antifolate (NSC139105) in man.

Authors:  D J Stewart; M Leavens; K Lu; Y M Wang; R S Benjamin; D H Ho; H Y Yap; T L Loo
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

Review 6.  Clinical pharmacokinetics of commonly used anticancer drugs.

Authors:  F M Balis; J S Holcenberg; W A Bleyer
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

7.  Effect of methotrexate on the pharmacokinetics and renal excretion of cisplatin.

Authors:  R Preiss; V K Brovtsyn; N I Perevodchikova; M B Bychkov; H Hüller; L A Belova; P Michailov
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

8.  Neurocognitive and Patient-Reported Outcomes in Adult Survivors of Childhood Osteosarcoma.

Authors:  Michelle N Edelmann; Vinay M Daryani; Michael W Bishop; Wei Liu; Tara M Brinkman; Clinton F Stewart; Daniel A Mulrooney; Cara Kimberg; Kirsten K Ness; Yin Ting Cheung; Deo Kumar Srivastava; Leslie L Robison; Melissa M Hudson; Kevin R Krull
Journal:  JAMA Oncol       Date:  2016-02       Impact factor: 31.777

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.